Pilot Study to Study the Time Between Pleuropulmonary Ultrasound and Antibiotic Therapy Prescription in Patients Admitted to the Emergency Department for Suspected Pneumonia (PRE-EPPA)

Pneumonia is a common pathology with significant morbidity and mortality. It is recommended in his diagnostic approach to perform either a chest X-ray or a pleuropulmonary ultrasound. Previous studies have shown the advantages of ultrasound in terms of diagnostic performance cost and patient irradiation. However, it remains little used in clinical practice.

Study Overview

• Status: Not yet recruiting
• Conditions: Pneumonia
• Intervention / Treatment: Procedure: Pleuropulmonary ultrasound performed by the investigator for patient with suspicion od Pneumonia

Detailed Description

The study will be conducted in the Emergency Department of grenoble University Hospital.

Patient admitted to the emergency department for respiratory symptoms (cough, fever, and/or dyspnea) will be enrolled in the study according to the inclusion and non-inclusion criteria and after obtaining his consent.

The investigator will perform the pleuropulmonary ultrasound following the clinical examination carried out by the physician in charge of the patient.

The patient's care is unaffected by the pleuropulmonary ultrasound's outcome, which is unknown to the physician in charge of the patient.

Data collection after the patient's discharge from the emergency department.

• Study Type: Observational
• Enrollment (Estimated): 15

Contacts and Locations

• Study Contact: Name: Alice GREMBER, MD; Phone Number: 0033476766784; Email: AGrember@chu-grenoble.fr
• Study Contact Backup: Name: Marcelline BUFFIN; Phone Number: 0033476766784; Email: Mbuffin@chu-grenoble.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patient admitted in the emergency department of Grenoble Alpes University Hospital for suspicion of Pneumonia

Description

Inclusion Criteria:

• Patient over 18 years admitted the the emergency department of Grenoble Alpes University Hospital with respiratory symptoms (cough and/or dyspnea, fever).
• No objection by the subject to the study
• Affiliated to the french social security system (or equivalent)

Exclusion Criteria:

• Patient admitted to a life-threatening emergency
• Patient already on antibiotic therapy on admission
• Patient excluded from another study
• Patient with respiratory signs following chest trauma
• Unable to communicate or non-french speaking patients or those with impaired comprehension or consciousness
• Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)
• The patient already enrolled in the study

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patient admitted for suspicion of Pneumonia; Patient admitted in emergency department of Grenoble Alpes University Hospital for suspicion of Pneumonia	Procedure: Pleuropulmonary ultrasound performed by the investigator for patient with suspicion od Pneumonia; In addition to the traditional management done by the physician at the patient's expense (such as clinical examination and paraclinical examinations like biology, chest X-ray, etc.), the investigator will perform pleuropulmonary ultrasound.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time between the antibiotic prescription and the pleuropulmonary ultrasonography used to detect pneumonia	Time between the antibiotic prescription and the pleuropulmonary ultrasonography used to detect pneumonia	1 hour

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Calculation of the predictive values of the pleuropulmonary ultrasound for pneumonia diagnosis	Calculation of the predictive values of the pleuropulmonary ultrasound for pneumonia diagnosis: area under the curve, sensitivity, specificity, positive predictive value, negative predictive value.	1 day
duration of performing the pleuropulmonary ultrasound	duration of performing the pleuropulmonary ultrasound	5 minutes
Time between the patient's admission to the emergency department and the completion of the pleuropulmonary ultrasound	Time between the patient's admission to the emergency department and the completion of the pleuropulmonary ultrasound	1 hour
4. Time between the performance of the pleuropulmonary ultrasound and the performance of the chest X-ray	4. Time between the performance of the pleuropulmonary ultrasound and the performance of the chest X-ray	2 hours

Collaborators and Investigators

• Sponsor: University Hospital, Grenoble
• Investigators: Principal Investigator: Alice GREMBER, MD, University Hospital, Grenoble

Study record dates

Study Major Dates

• Study Start (Estimated): July 13, 2026
• Primary Completion (Estimated): August 30, 2026
• Study Completion (Estimated): September 30, 2026

Study Registration Dates

• First Submitted: July 9, 2026
• First Submitted That Met QC Criteria: July 9, 2026
• First Posted (Actual): July 14, 2026

Study Record Updates

• Last Update Posted (Actual): July 14, 2026
• Last Update Submitted That Met QC Criteria: July 9, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Pneumonia; Antibiotic; Pleuropulmonary ultrasound
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia
• Other Study ID Numbers: 38RC26.0148; IDRCB :2026-A00930-51 (Other Identifier: CPP NORD OUEST IV (French Ethics Committees))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

The international writing and publication rules (The Uniform Requirements for Manuscripts of the ICMJE, April 2010) will be followed. The minimum anonymized source data for performing the statistical analysis will be made public at the time of publication, with the article, or deposited in an appropriate public database. Other anonymized data may be available from the principal investigator upon reasonable request and with the consent of the sponsor.

In accordance with the French law n ° 2002-303 of March 4th, 2002, the subjects can be informed, at their request, of the overall results of the research. In this study, the investigators commit to individually communicating the overall results to each subject participating in the research by a short (popularized) summary and associated with a copy of the scientific article.

• IPD Sharing Time Frame: At the time of the publication
• IPD Sharing Access Criteria: The international writing and publication rules (The Uniform Requirements for Manuscripts of the ICMJE, April 2010) will be followed. Moreover, In accordance with the French law n ° 2002-303 of March 4th, 2002
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No